+91 789 2456 581 | info@nckpharma.com

Please sign in first

Username

Password

Lost Your Password?

Not a member?

Please simply create an account before buying/booking any courses.

Create an account for free!

Home
- About Us
- Contact
NCK services
Course List
Admission
Corporate Training
Knowledge Base

Home
- About Us
- Contact
NCK services
Course List
Admission
Corporate Training
Knowledge Base

Pharma News

Keep updating your pharma knowledge

24 Sep 2017

What are the major differences between – Breakthrough Therapy Designation Vs. Fast Track Designation Vs. Priority Review Designation Vs. Accelerated Approval

/

Posted Byadmin

/

Comments0

/

TagsAccelerated Approval, Breakthrough Therapy designation, Fast Track designation, FDA grants Priority Review for potential new indication for Brilinta, priority review, Priority Review Designation, usfda accelerated approval

Here is a quick comparison of the USFDA drug development expedited programs. This may help you to distinguishing all of them effectively.

Related Articles

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
Turalio: USFDA approval of first therapy for rare joint tumor
Case Study: US FDA priority review grants for BMS’s sBLA for Opdivo to treat patients with resected high-risk advanced melanoma
BMS Opdivo+Yervoy combo received USFDA new indication approval.
US FDA grants priority review status to Novartis’ sickle cell molecule crizanlizumab
Quick look into Roche’s Tecentriq US FDA priority review grant

European approval for Roche’s tocilizumab for the treatment of giant cell arteritis (GCA)

USFDA approval of Verzenio to treat certain advanced/metastatic breast cancers

About Post Author

admin

Leave a Reply Cancel Reply

Search With Term

Recent Industry Update

Case Study: 505(b)(2) filing pathway – USFDA approval of Vumerity
What is the significance of Clinical Hold of investigational molecules?
US FDA places partial hold on Novartis’ AVXS-101 intrathecal study
Zentiva to acquire CEE pharma business of Alvogen
Insighht on USFDA approval of Trikafta
How much is the average ideal royalty rate in pharmaceutical and biopharmaceutical business deal?
Pharma Licensing: Explore differences between Royalty rate & Royalty base
Takeda Divesting Select OTC and Non-core Assets of takeda to Acino
GSK to disinvest Rabipur and Encepur – vaccine for USD 1.1 billion
S. Korea’s Mediforum acquires local pharma firms C-TRI, i-World Pharm
US FDA issued warning letter to Glenmark for Baddi plant
Alexion acquisition of Achillion: A 1 Billion Pharma Strategic Deal
New Drug Approval Case Study: USFDA approval of Galderma’s Aklief cream
Prometheus Biosciences collaboration deal with Takeda for targeted therapies for IBD
Biocon, Mylan launch first insulin glargine biosimilar, Semglee in Australia
USFDA approval of Rituxan, in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients 2 years of age and older
AstraZeneca divests Losec (omeprazole) and associated brands rights to Cheplapharm Arzneimittel GmbH
What is indication splitting licensing in pharmaceutical and bio-pharmaceutical business?
Bactiguard entered Licensing deal for Orthorthopedic trauma implants with Zimmer Biomet
AstraZeneca to launch QTERN in India with DCGI marketing authorization approval
FDA approved Rybelsus (semaglutide): first oral GLP-1 treatment for type 2 diabetes
Bayer received EU marketing authorization for the precision oncology treatment Vitrakvi (larotrectinib)
Clovis in-licensing deal for cancer program from 3B Pharmaceuticals
Biocon Ltd acquired a R&D facility from Pfizer
Pharma acquisition case study: Lundbeck to acquire Alder BioPharmaceuticals for US$ 1.95 billion
Insight on submission of USFDA sBLA of Tremfya (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA)
Mitsubishi Tanabe Pharma, Daiichi Sankyo enters licensing agreement for ALS treatment agent edaravone in Brazil
Alexion’s inlicensing deal for Amyloidosis Candidate In Japan
Insight on Boehringer Ingelheim’s new indication approval for Ofev to slow the rate of decline in pulmonary function in patients with Ssc-ILD
Sanofi India announces sale of its Ankleshwar facility to Zentiva

Monthly Archieves

Certification Courses

View our online Certification Courses.

Related Articles

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
Turalio: USFDA approval of first therapy for rare joint tumor
Case Study: US FDA priority review grants for BMS’s sBLA for Opdivo to treat patients with resected high-risk advanced melanoma
BMS Opdivo+Yervoy combo received USFDA new indication approval.
US FDA grants priority review status to Novartis’ sickle cell molecule crizanlizumab
Quick look into Roche’s Tecentriq US FDA priority review grant

Corporate Training

View list of courses, simulation, e-books, libararies for Pharma Corporate, Government and Regulatory Bodies.

Related Articles

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
Turalio: USFDA approval of first therapy for rare joint tumor
Case Study: US FDA priority review grants for BMS’s sBLA for Opdivo to treat patients with resected high-risk advanced melanoma
BMS Opdivo+Yervoy combo received USFDA new indication approval.
US FDA grants priority review status to Novartis’ sickle cell molecule crizanlizumab
Quick look into Roche’s Tecentriq US FDA priority review grant

Subscribe to NCK Newsline

Enter your email address:

Delivered by FeedBurner

Popular 1 Year Courses

KPE – C- 024 KPE’s Executive Program in Pharmaceutical Global Business
KPE-C-001 KPE’s Advance Diploma in Pharmaceutical Product Management
KPE-C-003 KPE’s Advance Diploma in Drug Regulatory Affairs
KPE-C-004 KPE’s Advance Diploma in Pharma Marketing
KPE – C- 009 KPE’s Advance Diploma in Pharmacovigilance
KPE-C-005 KPE’s Advance Diploma in Pharmaceutical Production management
KPE-C-08 KPE’s Advance Diploma in Pharmaceutical Strategic Business Management

Javascript is disabled

Javascript is disabled on your browser. Please enable it in order to use this form.

Loading

Query

First Name

Last Name

Email Address

Your Query *

Write Here

4 plus 4 equals?*

Prove you are a human

Write here

Your form has been submitted

Thank you %NAME% for the submitting your query/feedback.

Server Side Error

We faced problems while connecting to the server or receiving data from the server. Please wait for a few seconds and try again.

If the problem persists, then check your internet connectivity. If all other sites open fine, then please contact the administrator of this website with the following information.

TextStatus: undefined
HTTP Error: undefined

Processing your request

Error

Some error has occured.

Disclaimer & Privacy Policy | Terms of Use

Copyright © 2014 - 2015 All Right Reserved - NCK Pharma Solution Private Limited

This website uses cookies to improve your learning experience. Ok Privacy Policy

Privacy & Cookies Policy

Necessary Always Enabled

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests

etc.